ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Relmada Provides Enrollment Update in REL-1017 Study
americanpharmaceuticalreview
September 20, 2018Relmada Therapeutics announces that since dosing the first subject on June 27, 2017, 25% of the planned subjects received treatment in its Phase 2 study of dextromethadone (REL-1017) in depression.
Pharma Sources Insight January 2025
